EUVIMEDEUVIMED entdecken
Open Access

The Effect of Isoniazid for Tuberculosis Prevention on Pregnancy Risk Among Women Living With HIV on Antiretroviral Treatment and Progestin‐Based Hormonal Contraception

Karen Diepstra, Daniel Westreich, Agatha Bula, Clara Lemani, John Chapola, Jennifer Winston, Katie Mollan, Jill Hagey, Sam Phiri, Jane Chiwoko, Lameck Chinula, Mina C Hosseinipour und 4 weitere

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Karen Diepstra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Isoniazid, HIV Infections, Tuberculosis, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIH HHS, National Research Service Award Infectious Disease Training.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Concomitant use of antiretroviral therapy (ART), hormonal contraception, and isonicotinic acid hydrazide (isoniazid) for tuberculosis prevention is common among women of reproductive age who are living with HIV in sub‐Saharan Africa. We estimated the effect of isoniazid on 6‐month pregnancy risk among Malawian women living with HIV in the Family Planning and Antiretroviral Therapy (FP‐ART) prospective cohort study, overall and among subgroups defined by ART regimen type and hormonal contraceptive method.

Methods

The analytic sample included visits contributed by participants who were currently using either efavirenz‐ or dolutegravir‐based ART and either depot medroxyprogesterone acetate (DMPA) or levonorgestrel (LNG) implant contraception at the time of the visit. The exposure was self‐reported, current isoniazid use (yes/no). The binary outcome measure, 6‐month pregnancy, was defined as an estimated conception date 1–183 days after the study visit date. We used a marginal structural linear risk regression model with inverse probability of treatment weights, multiple imputation by chained equations, and bootstrapping to estimate risk differences (RD) and 95% confidence intervals (CI).

Results

The analytic sample included 4709 study visits occurring between September 2017 and June 2021. The weighted 6‐month pregnancy risk among isoniazid use visits was 3.0% compared with 2.3% among non‐use visits (RD 0.7%, 95% CI: −0.7%, 2.1%), and the results were qualitatively similar for all subgroup estimates.

Conclusions

We did not find a clinically significant effect of isoniazid use on 6‐month pregnancy incidence among women concomitantly using ART and either DMPA or LNG implant contraception.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidHIV InfectionsTuberculosisAntitubercular AgentsHumansFemalePregnancyAdultProspective StudiesYoung AdultMalawiAnti-HIV AgentsAdolescentLevonorgestrelMedroxyprogesterone AcetateContraceptive Agents, HormonalProgestinsHormonal ContraceptionCohort Studies

Stichwörter der Autor:innen

HIV/AIDSdrug–drug interactionhormonal contraceptionisoniazidpregnancy

Substanzen

IsoniazidAntitubercular AgentsAnti-HIV AgentsLevonorgestrelMedroxyprogesterone AcetateContraceptive Agents, HormonalProgestins

Autor:innen und Institutionen

  • Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • UNC Project-Malawi, Lilongwe, Malawi.
  • School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • School of Medicine, Duke University, Durham, North Carolina, USA.
  • The Lighthouse Trust, Lilongwe, Malawi.
  • School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Förderung

  • NICHD NIH HHS
  • NIH HHS
  • National Research Service Award Infectious Disease Training
  • FIC NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Diepstra, K., Westreich, D., Bula, A., Lemani, C., Chapola, J., Winston, J., Mollan, K., Hagey, J., Phiri, S., Chiwoko, J., Chinula, L., Hosseinipour, M. C., Cottrell, M., Pettifor, A., Wood, M. E., & Tang, J. H. (2025). The Effect of Isoniazid for Tuberculosis Prevention on Pregnancy Risk Among Women Living With HIV on Antiretroviral Treatment and Progestin‐Based Hormonal Contraception. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70105

Vancouver

Diepstra K, Westreich D, Bula A, Lemani C, Chapola J, Winston J, et al. The Effect of Isoniazid for Tuberculosis Prevention on Pregnancy Risk Among Women Living With HIV on Antiretroviral Treatment and Progestin‐Based Hormonal Contraception. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70105

BibTeX
@article{Diepstra2025,
  author = {Diepstra, Karen and Westreich, Daniel and Bula, Agatha and Lemani, Clara and Chapola, John and Winston, Jennifer and Mollan, Katie and Hagey, Jill and Phiri, Sam and Chiwoko, Jane and Chinula, Lameck and Hosseinipour, Mina C and Cottrell, Mackenzie and Pettifor, Audrey and Wood, Mollie E and Tang, Jennifer H},
  title = {The Effect of Isoniazid for Tuberculosis Prevention on Pregnancy Risk Among Women Living With HIV on Antiretroviral Treatment and Progestin‐Based Hormonal Contraception},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70105}
}
Kostenlos starten →